SMMT - Summit Therapeutics PLC - Stock & Dividends

Summit Therapeutics PLC is a biopharmaceutical company that specializes in the discovery, development, and commercialization of innovative medicines that prioritize the needs of patients, physicians, caregivers, and society as a whole.

The company's flagship development candidate is Ivonescimab, a cutting-edge bispecific antibody designed for immunotherapy. This novel treatment works by blocking PD-1, a key immune checkpoint, while also inhibiting angiogenesis, the formation of new blood vessels that feed cancer cells. This dual-action approach has the potential to revolutionize cancer treatment.

In addition to its oncology focus, Summit Therapeutics is also developing a portfolio of anti-infective therapies, including SMT-738, a pioneering class of precision antibiotics. These antibiotics are specifically designed to combat multidrug-resistant infections, such as carbapenem-resistant Enterobacteriaceae (CRE) infections, which pose a significant threat to public health.

To accelerate the development of its lead candidate, Ivonescimab, Summit Therapeutics has established strategic partnerships with industry leaders, including Akeso, Inc. and its affiliates, with whom it has a collaboration and license agreement. The company has also formed a strategic alliance with The University of Texas MD Anderson Cancer Center, a world-renowned institution, to expedite the development of Ivonescimab.

Founded in 2003, Summit Therapeutics PLC is headquartered in Miami, Florida, and is committed to improving human health through innovative, patient-centric therapies. For more information, please visit the company's website at https://www.summittxinc.com.